Developing a vaccine for a serious childhood illness caused by a virus.
Advanced Development of a Vaccine for Acute Flaccid Myelitis Associated with Enterovirus D68
This study is working on a new vaccine to help protect children from Acute Flaccid Myelitis (AFM), a serious condition linked to a virus, and it aims to eventually test the vaccine's safety and effectiveness in kids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intravacc B.v. NIH-funded |
| Lab location | 1 site (Bilthoven, Netherlands) |
| Project ID | NIH-11250792 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine specifically for Acute Flaccid Myelitis (AFM), a rare but severe condition that affects children and is associated with the Enterovirus D68. The project involves formulating and manufacturing vaccine components, conducting stability tests, and performing efficacy assessments using animal models. It aims to advance to early-stage clinical trials to evaluate the vaccine's safety and effectiveness in pediatric populations. The ultimate goal is to provide a preventive measure against AFM outbreaks.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research are children who are at risk of developing Acute Flaccid Myelitis due to Enterovirus D68 infections.
Not a fit: Patients who are adults or those who do not have a history of Enterovirus D68 infections may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a vaccine that protects children from Acute Flaccid Myelitis, potentially reducing the incidence of this debilitating condition.
How similar studies have performed: Other research has shown promise in developing vaccines for viral infections, indicating that this approach has potential for success.
Where this research is happening
Bilthoven, Netherlands
- Intravacc B.v. — Bilthoven, Netherlands (Active)
Researchers
- Principal investigator: Oosterhoff, Dinja — Intravacc B.v.
- Study coordinator: Oosterhoff, Dinja
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.